Literature DB >> 25363502

Decreasing prevalence of HCV coinfection in all risk groups for HIV infection between 2004 and 2011 in Spain.

S Serrano-Villar1, P Sobrino-Vegas, S Monge, F Dronda, A Hernando, M Montero, P Viciana, B Clotet, J A Pineda, J Del Amo, S Moreno.   

Abstract

While hepatitis C virus (HCV) infection seems to be expanding among HIV-infected men who have sex with men (MSM), the rate of coinfection in intravenous drug users (IDU) is assumed to remain constant. We evaluated the serial prevalence of HIV/HCV coinfection across all risk groups for HIV infection in Spain. We used data from 7045 subjects included in the multicentre, prospective Spanish Cohort of Adult HIV-infected Patients (CoRIS) between 2004 and 2011. We analysed risk factors for HIV/HCV coinfection by logistic regression analyses. The prevalence of HIV/HCV coinfection decreased from 25.3% (95% CI, 23.1-27.5) in 2004-2005 to 8.2% (95% CI, 6.9-9.5) in 2010-2011. This trend was consistently observed from 2004 to 2011 among all risk groups: IDU, 92.4% to 81.4%; MSM, 4.7% to 2.6%; heterosexual men, 13.0-8.9%; and heterosexual women, 14.5-4.0% (all P < 0.05). Strongest risk factors for HIV/HCV coinfection were IDU (OR, 54.9; 95% CI, 39.4-76.4), birth decade 1961-1970 (OR, 2.1; 95% CI, 1.1-3.7) and low educational level (OR, 2.4; 95% CI, 1.6-3.5). Hence, the prevalence of HIV/HCV coinfection decreased in Spain between 2004 and 2011. This decline was observed across all risk groups and is likely to be explained by a declining burden of HCV in the general population.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  HCV; HIV; coinfection; injection drug use; men who have sex with men; prevalence

Mesh:

Year:  2014        PMID: 25363502     DOI: 10.1111/jvh.12353

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  7 in total

1.  Evolving trends in the prevalence of hepatitis C virus antibody positivity among HIV-infected men in a community-based primary care setting.

Authors:  Yun-Chi Chen; Chloe L Thio; Farin Kamangar; Andrea L Cox; Kjell J Wiberg
Journal:  J Viral Hepat       Date:  2020-08-02       Impact factor: 3.728

2.  Incidence of hepatitis C virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: increasing rates of HCV diagnosis but not of HCV seroconversions.

Authors:  Paz Sobrino-Vegas; Susana Monge Corella; Sergio Serrano-Villar; Félix Gutiérrez; José Ramón Blanco; Ignacio Santos; Jorge del Romero; Ferrán Segura; Joaquín Portilla; Santiago Moreno Guillén; Julia del Amo
Journal:  PLoS One       Date:  2014-12-30       Impact factor: 3.240

3.  Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy.

Authors:  A Rivero-Juarez; L F Lopez-Cortes; M Castaño; D Merino; M Marquez; M Mancebo; F Cuenca-Lopez; P Jimenez-Aguilar; I Lopez-Montesinos; S Lopez-Cardenas; A Collado; M A Lopez-Ruz; M Omar; F Tellez; X Perez-Stachowski; J Hernandez-Quero; J A Girón-Gonzalez; E Fernandez-Fuertes; A Rivero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-10-27       Impact factor: 3.267

4.  Trends of recent hepatitis C virus infection among HIV-positive men who have sex with men in Taiwan, 2011-2018.

Authors:  Shu-Yuan Ho; Li-Hsin Su; Hsin-Yun Sun; Yu-Shan Huang; Yu-Chung Chuang; Miao-Hui Huang; Wen-Chun Liu; Yi-Ching Su; Pi-Han Lin; Sui-Yuan Chang; Chien-Ching Hung
Journal:  EClinicalMedicine       Date:  2020-06-27

5.  Genetic markers of lipid metabolism genes associated with low susceptibility to HCV infection.

Authors:  Luis Miguel Real; Juan Macías; Antonio Rivero-Juárez; Francisco Téllez; Dolores Merino; Sonia Moreno-Grau; Adelina Orellana; Juan Gómez-Salgado; María E Sáez; Mario Frías; Anaïs Corma-Gómez; Nicolás Merchante; Agustín Ruiz; Antonio Caruz; Juan A Pineda
Journal:  Sci Rep       Date:  2019-06-21       Impact factor: 4.379

6.  Hepatitis C treatment initiation in HIV-HCV coinfected patients.

Authors:  Laurent Cotte; Pascal Pugliese; Marc-Antoine Valantin; Lise Cuzin; Eric Billaud; Claudine Duvivier; Alissa Naqvi; Antoine Cheret; David Rey; Pierre Pradat; Isabelle Poizot-Martin
Journal:  BMC Infect Dis       Date:  2016-07-22       Impact factor: 3.090

7.  What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: a modeling analysis.

Authors:  Britt Skaathun; Annick Borquez; Antonio Rivero-Juarez; Sanjay R Mehta; Francisco Tellez; Manuel Castaño-Carracedo; Dolores Merino; Rosario Palacios; Juan Macías; Antonio Rivero; Natasha K Martin
Journal:  BMC Infect Dis       Date:  2020-08-08       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.